The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Visual abstract | Key updates to the GRAPPA treatment recommendations for PsA
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
In patients with PsA and congestive heart failure, which PsA treatment should be avoided?
A
B
C
D
The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing key updates to the GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) recommendations for the treatment of psoriatic arthritis.
The original GRAPPA guidelines were published in 2009 and revised in 2015.1 These new, updated, 2021 guidelines aim to offer recommendations for the use of therapies for the six psoriatic arthritis domains (peripheral arthritis, axial disease, enthesitis, dactylitis, psoriasis, and nail disease), giving guidance on treatments that can and cannot be used with associated conditions (inflammatory bowel disease and uveitis) and other comorbidities. Subcommittees were formed from GRAPPA members, with systemic literature searches completed using data published between 2013 and 2020. Treatment pathway recommendations consider the domains involved in psoriatic arthritis, patient treatment preferences, and current therapies. Additional position statements were added to address treatment with biosimilars and tapering, plus a revised research agenda.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content